Olutasidenib Investigational Agent Administration
MCC-25-22096
Phase 1 small_molecule active
Quick answer
Olutasidenib Investigational Agent Administration for Acute Myeloid Leukemia is a Phase 1 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RIGEL PHARMACEUTICALS INC
- Indication
- Acute Myeloid Leukemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active